These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 27805575)

  • 21. A Combined Prospective and Retrospective Comparison of Long-Term Functional Outcomes Suggests Delayed Loss of Ambulation and Pulmonary Decline with Long-Term Eteplirsen Treatment.
    Mitelman O; Abdel-Hamid HZ; Byrne BJ; Connolly AM; Heydemann P; Proud C; Shieh PB; Wagner KR; Dugar A; Santra S; Signorovitch J; Goemans N; ; McDonald CM; ; Mercuri E; ; Mendell JR
    J Neuromuscul Dis; 2022; 9(1):39-52. PubMed ID: 34420980
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Patients organizations and new drug approval in the US. Eteplirsen and Duchenne muscular dystrophy case].
    Dal-Ré R; Lopez de Munain A; Ayuso C
    Rev Neurol; 2017 Oct; 65(8):373-380. PubMed ID: 28990648
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The case for eteplirsen: Paving the way for precision medicine.
    Miceli MC; Nelson SF
    Mol Genet Metab; 2016 Jun; 118(2):70-1. PubMed ID: 27102846
    [No Abstract]   [Full Text] [Related]  

  • 24. Exon-skipping therapy for Duchenne muscular dystrophy.
    Nakamura A; Takeda S
    Lancet; 2011 Aug; 378(9791):546-7. PubMed ID: 21784507
    [No Abstract]   [Full Text] [Related]  

  • 25. Survival in eteplirsen-treated Duchenne Muscular Dystrophy patients: Are there benefits beyond steroids?
    Burnette WB
    Muscle Nerve; 2024 Jul; 70(1):4-5. PubMed ID: 38708792
    [No Abstract]   [Full Text] [Related]  

  • 26. Genetics and emerging treatments for Duchenne and Becker muscular dystrophy.
    Wein N; Alfano L; Flanigan KM
    Pediatr Clin North Am; 2015 Jun; 62(3):723-42. PubMed ID: 26022172
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Genetic therapies for inherited neuromuscular disorders.
    Scoto M; Finkel R; Mercuri E; Muntoni F
    Lancet Child Adolesc Health; 2018 Aug; 2(8):600-609. PubMed ID: 30119719
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Exon skipping, a therapy for Duchenne muscular dystrophy. Interview by Guenter Scheuerbrandt.
    Platenburg G
    Acta Myol; 2008 Oct; 27():69-73. PubMed ID: 19364065
    [No Abstract]   [Full Text] [Related]  

  • 29. Regarding "Eteplirsen for the treatment of Duchenne muscular dystrophy".
    Unger EF; Califf RM
    Ann Neurol; 2017 Jan; 81(1):162-164. PubMed ID: 27997035
    [No Abstract]   [Full Text] [Related]  

  • 30. [Not Available].
    Kaplan JC
    Med Sci (Paris); 2016 Nov; 32 Hors série n°2():57-59. PubMed ID: 27869079
    [No Abstract]   [Full Text] [Related]  

  • 31. Skipping, Steroids, and Genes: The First 7 Therapies for Duchenne Muscular Dystrophy.
    Kang PB
    Neurology; 2024 Mar; 102(5):e209210. PubMed ID: 38335475
    [No Abstract]   [Full Text] [Related]  

  • 32. [Exon skipping approach to Duchenne muscular dystorphy].
    Takeda S
    Rinsho Shinkeigaku; 2014; 54(12):1071-3. PubMed ID: 25672711
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Year in review 2019: Neuromuscular diseases.
    Birnkrant DJ; Black JB
    Pediatr Pulmonol; 2020 Oct; 55(10):2542-2546. PubMed ID: 32691988
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Real-world evidence of eteplirsen treatment effects in patients with Duchenne muscular dystrophy in the USA.
    Iff J; Zhong Y; Tuttle E; Gupta D; Paul X; Erik Henricson
    J Comp Eff Res; 2023 Sep; 12(9):e230086. PubMed ID: 37610303
    [No Abstract]   [Full Text] [Related]  

  • 35. Muscular dystrophy drug looks set for commercial success despite clinical doubts.
    Dyer O
    BMJ; 2016 Oct; 355():i5346. PubMed ID: 27698204
    [No Abstract]   [Full Text] [Related]  

  • 36. To skip or not to skip: that is the question for duchenne muscular dystrophy.
    Wood MJ
    Mol Ther; 2013 Dec; 21(12):2131-2. PubMed ID: 24317541
    [No Abstract]   [Full Text] [Related]  

  • 37. SPP1 genotype is a determinant of disease severity in Duchenne muscular dystrophy: predicting the severity of Duchenne muscular dystrophy: implications for treatment.
    Kyriakides T; Pegoraro E; Hoffman EP; Piva L; Cagnin S; Lanfranchi G; Griggs RC; Nelson SF
    Neurology; 2011 Nov; 77(20):1858; author reply 1858-9. PubMed ID: 22084278
    [No Abstract]   [Full Text] [Related]  

  • 38. The Dystrophinopathies.
    Thangarajh M
    Continuum (Minneap Minn); 2019 Dec; 25(6):1619-1639. PubMed ID: 31794463
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Reliable surrogate outcome measures in multicenter clinical trials of Duchenne muscular dystrophy.
    Mayhew JE; Florence JM; Mayhew TP; Henricson EK; Leshner RT; McCarter RJ; Escolar DM
    Muscle Nerve; 2007 Jan; 35(1):36-42. PubMed ID: 16969838
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Railroading at the FDA.
    Nat Biotechnol; 2016 Nov; 34(11):1078. PubMed ID: 27824847
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.